+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free

Pipeline Review of Rheumatoid Arthritis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

Pre Book Price: $ 5216

Original Price: $ 5795

Pipeline Review of Rheumatoid Arthritis Drugs Market: Snapshot 

Rheumatoid arthritis (RA) is an inflammatory and systemic form of arthritis that results in joint pain, inflammation, stiffness, and swelling. The rising prevalence of RA is one of the primary factors escalating the development of drugs for their treatment. About 4.9 million people across the major markets are suffering from this disorder. Prior to 1998, there were limited treatment options. The new treatment strategies available currently focus on early stage diagnosis, aggressive treatment, and continuous monitoring that have aided many patients in achieving their goals. 

RA continues to present economic and clinical challenges to patients, payers, and physicians. Various studies suggest that nearly half of the patients fail to maintain full-time employment within 10 years of onset. Cost-effective and clinically favorable treatments must emphasize on the prevention of disease progression and on enhancing the quality of productivity and life of patients. In accordance with the regulatory authorities, physicians prescribe several treatment options for patients, including anti–tumor necrosis factor (TNF) agents, biologics, disease-modifying antirheumatic drugs (DMARDs), interleukin (IL)-6 inhibitors, JAK inhibitors, or monoclonal antibodies. 

This research report provides a comprehensive overview of the global rheumatoid arthritis drugs market. It reviews the primary pipeline products under drug profile section, which involves MoA and research and development brief, product description, and details regarding licensing, collaboration, and other developmental activities. It profiles the key players involved in the discovery and development of RS drugs and offers insights into all their latest developments, deals, and projects. It provides an extensive coverage of pipeline products on the basis of various stages of development, ranging from pre-registration to discovery and undisclosed stages. For a coherent understanding, RA drugs pipeline is also explained in terms of MoA, route of administration, target, and molecule type. A summary of all the discontinued and dormant pipeline projects also forms an important part of the report. 

Pipeline Review of Rheumatoid Arthritis Drugs Market: Trends 

Over the past few years, there have been introduction of novel therapies, rapid accrual of evidence, amendments in recommendations, and the advancement of guidance development methodologies. The updated recommendations provide a treat-to-target guidance strategy for patients and clinicians in an era of rapid advances in the treatment of RA. In addition to a large treatment options available, various drugs including sirukumab and baricitinib are estimated to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of RA and other autoimmune conditions such as psoriatic arthritis and psoriasis in the near future. The patent expiration of some of the blockbuster drugs such as Humira, Remicade, and Enbrel in the forthcoming years will encourage the development of RA drugs. 

However, with the wide variety of treatment options available and more in the pipeline, the identification of the most economically and clinically effective allocation of treatments is becoming a significant challenge for payers. An increasing number of patients are switching between multiple therapies, making treatment protocol and formulary design complex. In addition, the whole treatment procedure has become more aggressive as physicians try to implement the adoption of expensive biologics earlier in the disease progression. 

Pipeline Review of Rheumatoid Arthritis Drugs Market: Region-wise Outlook 

The report meticulously studies the status of pipeline of RA drugs across North America, Europe, Asia Pacific, and Rest of the World. North America presents plethora of opportunities for development of drugs and enriching pipeline owing to the increasing investments for research and development. The presence of a large number of key players in the global rheumatoid arthritis drugs market, stringent regulations, and advanced healthcare and research infrastructure are supporting the growth of the segment. The Asia Pacific region will also flourish during the forecast period due to the rising incidence of RA. 

Companies Mentioned in the Report: 

Some of the key companies involved in the development of rheumatoid arthritis drugs are Isis Pharmaceuticals, Eli Lilly and Company, Johnson &Johnson, Inovio Biomedical Corporation, Merck & Co, AstraZeneca, GlaxoSmithKline, Santen Pharmaceutical, Amgen, Antares Pharma, Alcon, Biotest AG, and Bristol-Myers Squibb Company. 

Major regions analyzed under this research report are:

  • Europe
  • North America
  • Asia Pacific
  • Rest of the World 

This report gives you access to decisive data such as:

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for the coming years 

Key highlights of this report

  • Overview of key market forces propelling and restraining market growth
  • Up-to-date analyses of market trends and technological improvements
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors
  • An array of graphics and SWOT analysis of major industry segments
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis
  • Offers a clear understanding of the competitive landscape and key product segments

Note : All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Transparency Market Research.

To receive discount, please click on the button below.

Please click on the button below to customize this report.

Back To Top